Datavault AI Signs Letter of Intent for 19.9% Stake in DataMEDS AI, Expanding Health Data Monetization
Found this article helpful?
Share it with your network and spread the knowledge!
Datavault AI Inc. (NASDAQ: DVLT) has entered into a nonbinding letter of intent to acquire a 19.9% equity interest in DataMEDS AI Inc. (NASDAQ: MEDS) in exchange for expanding its existing technology license with the company. The proposed transaction, announced by Datavault AI (NASDAQ: DVLT), would allow Datavault AI to retain ownership of its underlying intellectual property while potentially generating royalty revenue from commercialization of the licensed technologies. DataMEDS would assume commercialization costs, and Datavault AI would have the right to designate one director to the DataMEDS board following closing. The company believes a fourth-quarter 2026 closing is achievable, subject to due diligence, definitive agreements and customary closing conditions.
The proposed expanded license would build on DataMEDS’ existing PharmacyChain platform and EinsteinRx AI capabilities, incorporating Datavault AI Health technologies designed to support patient-controlled health data access, management, monetization and tokenization across pharmacy, laboratory, wearable and other health care environments. This initiative is part of broader efforts by DataMEDS to expand its health care technology capabilities through arrangements with several companies, including EOS Technology Holdings, Scilex Holding Company, HealthBridge Advisors and REBOOT Health AI. The letter of intent does not obligate either party to complete the transaction. For full details, the press release is available at https://ibn.fm/Q8IGK.
The transaction matters for Texas because Datavault AI’s platform serves multiple industries, including healthcare, and the company’s Data Science division leverages Web 3.0 and high-performance computing for data perception, valuation and secure monetization. As businesses across the state seek to commercialize health data responsibly, the proposed arrangement could provide a model for retaining intellectual property while generating royalty revenue. Datavault AI is headquartered in Philadelphia, PA, but its technologies have broad applications that could benefit Texas companies in biotech, fintech, energy and other sectors. More information about Datavault AI is available at https://dvlt.ai, and the latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT.
The announcement was distributed through DefenseWireNews, a specialized communications platform focused on defense contractors, aerospace firms, cybersecurity leaders, advanced manufacturing innovators and other mission-critical companies. DefenseWireNews is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also provides article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. For full terms of use and disclaimers applicable to all content provided by DWN, see https://www.DefenseWireNews.com/Disclaimer.